Thomas Edward Schoenherr, CEO of Diagnostics at Tempus AI, Inc., filed a Form 4 on August 25, 2026, disclosing a sale of Class A Common Stock executed on August 21, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Thomas Edward Schoenherr, identified as CEO, Diagnostics of Tempus AI, Inc.
  • Shares sold: 2,694 shares of Class A Common Stock disposed of on August 21, 2026
  • Sale price: $70 per share
  • Remaining ownership: 87,021 shares of Class A Common Stock held directly following the transaction
  • Trading plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Schoenherr on March 3, 2026
  • Transaction code: "S" (sale), with the transaction marked as conducted under a Rule 10b5-1(c) plan

Schoenherr's Rule 10b5-1 Sale of Tempus AI Class A Shares

According to the filing, Thomas Edward Schoenherr, serving as CEO of Diagnostics at Tempus AI, Inc. (NASDAQ:TEM), disposed of 2,694 shares of Class A Common Stock at a price of $70 per share on August 21, 2026. The Form 4 was filed on August 25, 2026, and indicates the transaction was conducted directly, with Schoenherr retaining direct beneficial ownership of 87,021 shares following the reported sale.

The filing discloses that the transaction was made pursuant to a Rule 10b5-1 trading plan that Schoenherr adopted on March 3, 2026. The form's checkbox confirms the sale is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). No derivative securities were reported as acquired or disposed of in connection with this filing. The form was signed by Andrew Polovin as Attorney-in-Fact on August 25, 2026.

No Table II derivative security transactions were reported. The filing covers only the single Class A Common Stock sale described above, and no indirect ownership interests were disclosed for Schoenherr in connection with this transaction.

What Was Disclosed

The filing reports a single sale of 2,694 shares of Tempus AI Class A Common Stock by the CEO of Diagnostics at $70 per share on August 21, 2026, executed under a pre-established Rule 10b5-1 plan, leaving the reporting person with 87,021 directly held shares.